Clinical Research on the Efficacy of Thread-embedding Acupuncture on Herniated Intervertebral Disc of Lumbar Spine

February 5, 2020 updated by: Byung-Kwan Seo, Kyunghee University Medical Center

Clinical Research on the Efficacy and Safety of Thread-embedding Acupuncture for Treatment of Herniated Intervertebral Disc of Lumbar Spine; A Multicenter, Randomized, Patient-assessor Blinded, Controlled, Parallel Clinical Trial

This clinical trial is designed to evaluate the efficacy and safety of thread-embedding acupuncture for treatment of lumbar herniated intervertebral disc (L-HIVD) by assessing pain, function, and quality of life.

Study Overview

Detailed Description

Seventy patient between the ages of 19 and 70 with L-HIVD will be recruited by eligibility criteria and randomly allocated to the thread-embedding acupuncture (TEA) group and sham thread-embedding acupuncture (STEA) group. Both groups will receive treatment on predefined 23 acupoints once a week for 8 weeks, and needle with thread removed will be used in STEA group instead of normal TEA. 100 mm visual analogue scale (VAS) for low back pain will be assessed as a primary outcome. Also, 100mm VAS for radiating pain, Oswestry disability index (ODI), Rolland Morris disability questionnaire (RMDQ), EQ-5D-5L and global perceived effect (GPE) will be measured as secondary outcomes. All the outcomes will be assessed at baseline, 4 weeks after screening, treatment end (8 weeks, primary end point) and follow-up sessions (12 and 16 weeks).

Study Type

Interventional

Enrollment (Actual)

70

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Daegu, Korea, Republic of, 42158
        • Daegu Korean Medicine Hospital of Daegu Haany University
      • Seoul, Korea, Republic of, 05278
        • Kyung Hee University Hospital at Gangdong
      • Seoul, Korea, Republic of, 02447
        • Kyunghee University Medical Center
    • Gyeonggi
      • Seongnam, Gyeonggi, Korea, Republic of, 13601
        • Dongguk University Bundang Oriental Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

19 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Male or female adults aged 19-70
  2. Radiating pain matched with severer abnormality than bulging shown by CT or MRI on lumbar spine
  3. 40 or higher low back pain on 100mm pain VAS
  4. Volunteers who agree to participate and sign the Informed Consent Form, following a detailed explanation of clinical trials

Exclusion Criteria:

  1. Congenital abnormalities or surgical history on lumbar regions
  2. Red flag signs that may be suspected of cauda equina syndrome, such as bladder and bowel dysfunction or saddle anesthesia
  3. Tumor, fracture or infection in lumbar regions
  4. Injection treatment on lumbar regions within 1 week
  5. Psychiatric disorder currently undergoing treatment such as depression or schizophrenia
  6. Inappropriate condition for thread-embedding acupuncture due to skin disease or hemostatic disorder (PT INR > 2.0 or taking anticoagulant)
  7. Other diseases that could affect or interfere with therapeutic outcomes, including severe gastrointestinal disease, cardiovascular disease, hypertension, diabetes, renal disease, liver disease or thyroid disorder
  8. Contraindication of acetaminophen including intercurrent disease, hypersensitivity reaction or other medication
  9. Pregnant women or other inappropriate condition for thread-embedding acupuncture
  10. Heavy drinking (more than 3 cups per day) that could cause hepatotoxicity with acetaminophen

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Thread-Embedding Acupuncture (TEA)
The TEA group will be treated once a week for 8 weeks, using 29G x 40mm or 29G x 60mm TEA on predefined 23 acupoints selected by expert group according to STRICTA. All other treatment affecting the outcomes will be prohibited during the trial period. All therapeutic procedure will be performed by acupuncture specialists who have received training for the consensus of multicenter.

The acupoints and size of TEA are as follows:

  1. Both EX-B2 of herniated intervertebral disc level, its upper level and its lower level (6 acupoints): perpendicular insertion, 4cm
  2. Both BL24: transverse insertion toward L1 level along the erector muscle of spine, 6cm
  3. Both BL25: transverse insertion toward iliac crest, 4cm
  4. Both BL26: transverse insertion toward L1 level along the erector muscle of spine, 6cm
  5. Both BL26: oblique insertion toward iliolumbar ligament, 6cm
  6. Both EX-B7: oblique insertion toward gluteus medius muscle, 6cm
  7. Both BL28: oblique insertion toward sacroiliac ligament, 6cm
  8. Both GB30: perpendicular insertion, 6cm
  9. Symptomatic side GB34, BL57 and ST36: oblique insertion toward foot, 4cm
Sham Comparator: Sham Thread-Embedding Acupuncture (STEA)
The STEA group will be treated once a week for 8 weeks, using 29G x 40mm or 29G x 60mm sham TEA on predefined 23 acupoints selected by expert group according to STRICTA.
All procedure of STEA group, including acupoints and size of TEA will be same as that of TEA group. However, thread-removed TEA will be used for STEA group instead of normal TEA, and removing procedure of thread will be performed aseptic and secretly for patient-blinding and prevention of infection.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from Baseline 100mm Pain Visual Analogue Scale (VAS) for low back pain at Week 8
Time Frame: Week 1 (Baseline), Week 4, Week 8 (Primary end point, Treatment end), Week 12, Week 16 (F/U)
Measurement instrument for subjective pain
Week 1 (Baseline), Week 4, Week 8 (Primary end point, Treatment end), Week 12, Week 16 (F/U)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
100mm Pain Visual Analogue Scale (VAS) for radiating pain
Time Frame: Week 1 (Baseline), Week 4, Week 8 (Treatment end), Week 12, Week 16 (F/U)
Measurement instrument for subjective pain
Week 1 (Baseline), Week 4, Week 8 (Treatment end), Week 12, Week 16 (F/U)
Oswestry Disability Index (ODI)
Time Frame: Week 1 (Baseline), Week 4, Week 8 (Treatment end), Week 12, Week 16 (F/U)
Validated questionnaire for disability of low back pain.
Week 1 (Baseline), Week 4, Week 8 (Treatment end), Week 12, Week 16 (F/U)
EuroQol-5 dimensions-5 level (EQ-5D-5L)
Time Frame: Week 1 (Baseline), Week 4, Week 8 (Treatment end), Week 12, Week 16 (F/U)
Standardized instrument for generic health status
Week 1 (Baseline), Week 4, Week 8 (Treatment end), Week 12, Week 16 (F/U)
Roland-Morris Disability Questionnaire (RMDQ)
Time Frame: Week 1 (Baseline), Week 4, Week 8 (Treatment end), Week 12, Week 16 (F/U)
Health status measure for low back pain
Week 1 (Baseline), Week 4, Week 8 (Treatment end), Week 12, Week 16 (F/U)
Global Perceived Effect (GPE)
Time Frame: Week 4, Week 8 (Treatment end), Week 12, Week 16 (F/U)
Assessment of change in the patient's chief complaint
Week 4, Week 8 (Treatment end), Week 12, Week 16 (F/U)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Byung-Kwan Seo, PhD., KMD, Kyunghee University Medical Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 11, 2017

Primary Completion (Actual)

June 4, 2019

Study Completion (Actual)

July 30, 2019

Study Registration Dates

First Submitted

July 25, 2017

First Submitted That Met QC Criteria

July 28, 2017

First Posted (Actual)

August 2, 2017

Study Record Updates

Last Update Posted (Actual)

February 6, 2020

Last Update Submitted That Met QC Criteria

February 5, 2020

Last Verified

February 1, 2020

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Lumbar Disc Herniation

Clinical Trials on Thread-embedding Acupuncture (TEA)

3
Subscribe